Xilio Therapeutics, Inc. (XLO)
Key Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
|
Dr. Rene Russo BCPS, Pharm.D.
|
President, CEO & Director | 1.16M | -- | 1975 |
|
Mr. Christopher Frankenfield
|
CFO & COO | 941.59k | -- | 1982 |
|
Mr. Kevin M. Brennan
|
Senior Vice President of Finance & Accounting | -- | -- | 1970 |
|
Dr. Uli Bialucha Ph.D.
|
Chief Scientific Officer | -- | -- | -- |
|
Mr. Nathan McBride
|
Chief Information Officer | -- | -- | -- |
|
Mr. Benjamin S. Harshbarger J.D.
|
Chief Legal Officer | -- | -- | 1969 |
|
Dr. Scott Coleman Ph.D.
|
Chief Development Officer | -- | -- | -- |
|
Ms. Ruth du Moulin
|
Senior Vice President of Medical Affairs | -- | -- | -- |
|
Dr. Yariv Houvras M.D., Ph.D.
|
Chief Medical Officer | -- | -- | -- |
Xilio Therapeutics, Inc.
- Sector:
- Healthcare
- Industry: Biotechnology
- Full Time Employees:
- 76
Description
Xilio Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery and development of masked immuno-oncology therapies. The company's pipeline includes XTX501, a bispecific PD-1 / masked IL-2, for patients with metastatic non-small cell lung cancer; Efarindodekin alfa, an investigational, masked IL-12, that is in Phase 2 clinical trial for patients with advanced solid tumors; and Vilastobart, an investigational tumor-activated, Fc-enhanced, high affinity binding anti-CTLA-4 monoclonal antibody. The company was founded in 2016 and is headquartered in Waltham, Massachusetts.
Corporate Governance
Upcoming Events
Upcoming Events Information Not Available
Recent Events
May 27, 2026 at 12:00 AM UTC
CORRESP: A correspondence can be sent as a document with another submission type or can be sent as a separate submission
